8-K: Kura Oncology Reports Positive Clinical Trial Progress and Strong Financial Position in Q1 2024

Kura Oncology announced first quarter 2024 financial results, highlighted by a Breakthrough Therapy Designation for ziftomenib and a strong cash position of $527 million.

Summary

• Kura Oncology reported its first quarter 2024 financial results, showing a net loss of $49.5 million, compared to a net loss of $34.1 million in the same period last year.
• The company's research and development expenses increased to $36.3 million from $25.2 million year-over-year, while general and administrative expenses rose to $18.2 million from $11.4 million.
• Kura's cash, cash equivalents, and short-term investments totaled $527 million as of March 31, 2024, up from $424 million at the end of 2023, which includes $145.8 million from a private placement.
• The company received Breakthrough Therapy Designation from the FDA for ziftomenib in NPM1-mutant AML.
• Enrollment in the registration-directed trial of ziftomenib in NPM1-mutant AML is on track to complete by mid-2024.
• Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML was reported.
• The first patient was dosed with KO-2806 and cabozantinib in renal cell carcinoma.
• Management expects the current cash position to fund operations into 2027.

Sentiment

Score: 8

Explanation: The document is very positive due to the Breakthrough Therapy Designation, strong clinical trial results, and robust cash position. The increased net loss and expenses are a concern, but the overall tone is optimistic.

Positives

• The Breakthrough Therapy Designation for ziftomenib is a significant regulatory milestone.
• The company has a strong cash position of $527 million, ensuring funding into 2027.
• The 100% complete remission rate in newly diagnosed patients treated with ziftomenib and 7+3 is very promising.
• The company is progressing multiple clinical trials across different cancer types.
• The rapid enrollment in ziftomenib studies indicates strong investigator enthusiasm.

Negatives

• The net loss for the first quarter of 2024 increased to $49.5 million from $34.1 million in the same period last year.
• Research and development expenses increased to $36.3 million from $25.2 million year-over-year.
• General and administrative expenses also increased to $18.2 million from $11.4 million year-over-year.

Risks

• Clinical trials may not demonstrate safety and/or efficacy in later stages.
• The company may not obtain regulatory approval for its product candidates.
• There are risks associated with reliance on third parties to conduct clinical trials.
• The company relies on outside financing to meet capital requirements.
• There are risks associated with discovering, developing, and commercializing new drugs.

Future Outlook

Management expects that the current cash, cash equivalents, and short-term investments will fund operations into 2027, and the company has several milestones planned for the remainder of 2024 and into 2025.

Management Comments

• Ziftomenib continues to demonstrate a best-in-class safety and efficacy profile as well as optimal pharmaceutical properties, which we believe will enable it to become a cornerstone of therapy in acute leukemias and beyond, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
• This belief is backed by increasing investigator enthusiasm, as evidenced by rapid enrollment across our ongoing ziftomenib studies, and further supported by the FDAs decision to grant Breakthrough Therapy Designation (BTD) to ziftomenib.

Industry Context

The Breakthrough Therapy Designation for ziftomenib highlights the potential for targeted therapies in AML, a field with significant unmet medical need. The company's focus on precision medicines aligns with the broader industry trend towards personalized cancer treatments.

Comparison to Industry Standards

• The 35% complete response rate and 45% overall response rate in the Phase 1 trial of ziftomenib in heavily pretreated patients with NPM1-mutant AML is competitive with other targeted therapies in this space.
• The 100% complete remission rate in newly diagnosed patients treated with ziftomenib and 7+3 is a very strong result, exceeding typical outcomes with standard chemotherapy alone.
• The $527 million cash position is substantial for a clinical-stage biotech company, providing a significant runway compared to many peers.
• Companies like Agios Pharmaceuticals and Blueprint Medicines are also developing targeted therapies for hematologic malignancies, and Kura's results will be closely watched in comparison.

Stakeholder Impact

• Shareholders will likely view the Breakthrough Therapy Designation and strong cash position positively.
• Employees may be encouraged by the progress of the clinical trials and the company's financial stability.
• Patients with AML may benefit from the potential approval of ziftomenib.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Complete enrollment of 85 patients in the KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant R/R AML by mid-2024.
• Identify the recommended Phase 2 dose of ziftomenib in combination with venetoclax and azacitidine by mid-2024.
• Identify the recommended Phase 2 dose of ziftomenib in combination with 7+3 by mid-2024.
• Initiate Phase 1b expansion study of ziftomenib in combination with standards of care, including venetoclax/azacitidine in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, in the second half of 2024.
• Submit an investigational new drug application for ziftomenib in a solid tumor indication and present preclinical data at a medical meeting in the second half of 2024.
• Dose the first patients with KO-2806 and adagrasib in KRASG12C-mutated non-small cell lung cancer by mid-2024.
• Complete enrollment of two expansion cohorts in KURRENT-HN and identify the optimal biologically active dose of tipifarnib and alpelisib by the end of 2024.
• Present data from the KURRENT-HN trial of tipifarnib in combination with alpelisib in PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) in the first half of 2025.

Key Dates

Keywords

ziftomenib, AML, Kura Oncology, NPM1-mutant, KMT2A-rearranged, KO-2806, Breakthrough Therapy Designation, clinical trials, oncology, cancer, renal cell carcinoma, tipifarnib, venetoclax, azacitidine, cabozantinib, adagrasib